FDA approves Teva’s QVAR with dose counter to treat asthma – Pharmaceutical Business Review

FDA approves Teva's QVAR with dose counter to treat asthma
Pharmaceutical Business Review
The US Food and Drug Administration (FDA) has approved the use of Teva Pharmaceutical's QVAR (beclomethasone dipropionate HFA) with a dose counter for the ongoing treatment of asthma as a preventative therapy in patients five years of age and older.

View full post on asthma – Google News

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.